Endo is expected to have full ownership of the compounds developed under the collaboration with exclusive worldwide rights, and will fund all subsequent drug development and commercialisation activities. Endo will provide research funding and pay success-based discovery milestones payments to TCG Lifesciences.
Ivan Gergel, EVP of research and development at Endo, said: “We are excited to be working with TCG Lifesciences in our efforts to discover, develop and deliver the right kinds of treatment solutions to patients and providers. This collaboration is consistent with our strategy of building Endo’s pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts.”
Swapan Bhattacharya, managing director at TCG Lifesciences, said: “This partnership with Endo is a result of the skills, capabilities and scale of operations we have developed over the past few years at TCG Lifesciences and more specifically at Chembiotek.
“This also highlights TCG Lifesciences focus on developing special platform technologies, electrophysiology and specific animal models relevant to preclinical research in the area of pain. Our talented and dedicated team of scientists working in the area of medicinal chemistry, biology and animal pharmacology have made this possible.”